DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Setipiprant is an investigational drug.
There have been 4 clinical trials for Setipiprant. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2011.
The most common disease conditions in clinical trials are Alopecia Areata, Alopecia, and Rhinitis, Allergic, Seasonal. The leading clinical trial sponsors are Actelion, Allergan, and [disabled in preview].
There are two US patents protecting this investigational drug and twenty-nine international patents.
Recent Clinical Trials for Setipiprant
|Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males||Allergan||Phase 2|
|Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis||Actelion||Phase 3|
|A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)||Actelion||Phase 1|
Top disease conditions for Setipiprant
Top clinical trial sponsors for Setipiprant
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Setipiprant||See Pricing||Tetrahydropyridoindole derivatives||Actelion Pharmaceuticals, Ltd. (Allschwil, CH)||See Pricing|
|Setipiprant||See Pricing||Methods for the diagnosis and treatment of pulmonary fibrosis in subjects with hermansky pudlak syndrome||Brown University (Providence, RI) Yale University (New Haven, CT)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|